NEW YORK (360Dx) – As its first clinical test moves toward commercial launch this year in partnership with Genomic Health, Epic Sciences is ramping up development efforts for assays in new indications, and provided a first look at one, a PD-L1 assay, in a study published last month with collaborators at Yale University, the University of Southern California, and the University of California, San Diego.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.